{
  "schemaVersion": 1,
  "id": "research-315",
  "slug": "315-what-a-retatrutide-outcomes-trial-can-establish-about-kidney-events",
  "title": "What a retatrutide outcomes trial can establish about kidney events",
  "catalogLabel": "RETA / IGF-1 LR3",
  "productCollection": "https://heritagebiolabs.com/research-library/products/reta-igf-1-lr3",
  "productHandles": [
    "reta-igf-1-lr3-710",
    "reta-igf-1-lr3-711"
  ],
  "productUrls": [
    "https://heritagebiolabs.com/product/reta-igf-1-lr3-710",
    "https://heritagebiolabs.com/product/reta-igf-1-lr3-711"
  ],
  "readingFocus": "Study findings",
  "readingFocusNote": "Reading focus is a navigational tag, not an evidence grade.",
  "wordCount": 272,
  "sourceYears": [
    1995,
    2024,
    2026
  ],
  "paragraphs": [
    "Peptides are short amino-acid chains connected by peptide bonds. Some are made to activate particular hormone receptors. Retatrutide is an investigational peptide that acts on GIP, GLP-1 and glucagon receptors. IGF-1 LR3 is an engineered, extended version of the insulin-like growth factor 1 protein. This catalog entry names the two together. An ongoing retatrutide trial illustrates which kidney and heart outcomes are being studied for one component. [1, 2, 3]",
    "The TRIUMPH-Outcomes registry describes a randomized phase 3 comparison of retatrutide and placebo in people with excess body weight and cardiovascular disease, chronic kidney disease or both. Its cardiovascular and kidney outcome measures are designed to track events over time. This differs from an early study that records a short-term change in a blood marker or measures the size of an organ. A trial with clinical events can examine whether those events occur at different rates in the assigned groups. [1]",
    "An older experiment with IGF-1 LR3 in guinea pigs reported changes in organ growth and circulating growth-related factors. Organ size and kidney function are different outcomes. Changes in the first do not indicate a lower rate of the events planned for measurement in TRIUMPH-Outcomes. The animal study also used IGF-1 LR3 separately from retatrutide. [3]",
    "The registry lists no results by November 8, 2026, and it does not list an arm receiving IGF-1 LR3. I found no published clinical outcome comparison for the named pair. Data from the ongoing trial can answer the question about the assigned retatrutide intervention once results are available. Estimating the outcome of adding a growth-factor analog would require a comparison that includes it. [1, 2, 3]"
  ],
  "sources": [
    {
      "number": 1,
      "citation": "Eli Lilly and Company. A Phase 3, Randomized, Double-Blind, Placebo-Controlled, Event-Driven Study to Investigate the Effect of Retatrutide on the Incidence of Major Adverse Cardiovascular Events and Major Adverse Kidney Events in Participants With Body Mass Index ≥27 kg/m2 and Atherosclerotic Cardiovascular Disease and/or Chronic Kidney Disease. ClinicalTrials.gov (publication 2024-04-25, record updated 2026-10-08).",
      "url": "https://clinicaltrials.gov/study/NCT06383390"
    },
    {
      "number": 2,
      "citation": "Ania M. Jastreboff et al. Retatrutide, a Triple Hormone Receptor Agonist, for Treatment of Obesity. The New England Journal of Medicine (publication 2026-09-29).",
      "url": "https://pubmed.ncbi.nlm.nih.gov/42814954/"
    },
    {
      "number": 3,
      "citation": "M. A. Conlon et al. Long R3 insulin-like growth factor-I (IGF-I) infusion stimulates organ growth but reduces plasma IGF-I, IGF-II and IGF binding protein concentrations in the guinea pig. Journal of Endocrinology (publication 1995-08).",
      "url": "https://pubmed.ncbi.nlm.nih.gov/7561636/"
    }
  ],
  "canonicalUrl": "https://heritagebiolabs.com/research-library/articles/315-what-a-retatrutide-outcomes-trial-can-establish-about-kidney-events",
  "markdownUrl": "https://heritagebiolabs.com/research-library/data/articles/315-what-a-retatrutide-outcomes-trial-can-establish-about-kidney-events.md",
  "jsonUrl": "https://heritagebiolabs.com/research-library/data/articles/315-what-a-retatrutide-outcomes-trial-can-establish-about-kidney-events.json",
  "provenance": {
    "sourceArchive": "Peptide Research Articles - All 82 Volumes.zip",
    "sourceArchiveSha256": "9796bec477cbe2f8017dda81c7e58260985a13bdda1f934e8eb8d0549c2cada5",
    "sourceVolume": "Peptide Research Articles 063 - RETA GLP-3 and RETA IGF-1 LR3.docx",
    "sourceArticleNumber": 315,
    "contentSha256": "29c1ad83c12ebb4d8bd46d3a41300f606d4ca9deafa318d8e93e088f2a7fe3cb",
    "statement": "Article titles, body paragraphs and numbered citations extracted without rewriting from owner-supplied Word volumes. Product mappings use exact catalog labels; reading-focus tags and excerpts are navigational metadata. No independent peer-review or comprehensive source verification is claimed."
  },
  "scope": "Educational article about published research. For research use only; not medical advice. Literature does not establish the identity, purity or activity of a purchased lot, and studies of individual components do not validate a blend."
}
